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Abstract A wide variety of drugs can cause myoclonus.
To illustrate this, we first discuss two personally
observed cases, one presenting with generalized, but
facial-predominant, myoclonus that was induced by
amantadine; and the other presenting with propriospinal
myoclonus triggered by an antibiotic. We then review
the literature on drugs that may cause myoclonus,
extracting the corresponding clinical phenotype and
suggested underlying pathophysiology. The most fre-
quently reported classes of drugs causing myoclonus
include opiates, antidepressants, antipsychotics, and
antibiotics. The distribution of myoclonus ranges from
focal to generalized, even amongst patients using the
same drug, which suggests various neuro-anatomical
generators. Possible underlying pathophysiological
alterations involve serotonin, dopamine, GABA, and
glutamate-related processes at various levels of the
neuraxis. The high number of cases of drug-induced
myoclonus, together with their reported heterogeneous
clinical characteristics, underscores the importance of
considering drugs as a possible cause of myoclonus,
regardless of its clinical characteristics.
Keywords Drug-induced myoclonus  Myoclonus/
phenotype  Myoclonus/physiopathology
Introduction
Myoclonus are involuntary sudden, brief, shock-like
‘jerky’ movements due to muscular contractions (‘posi-
tive myoclonus’) or sudden lapses of muscle contraction
in active muscles (‘negative myoclonus’ or ‘asterixis’)
[40, 44]. Myoclonus can be classified by distribution
(focal, segmental, multifocal, and generalized) [75], by
localization of the ‘pulse generator’ (cortical, subcorti-
cal, brainstem, spinal, or peripheral) [44], and by aeti-
ology (physiological, essential, epileptic, symptomatic,
and psychogenic) [44, 52]. In this paper, we review the
phenomenon of drug-induced myoclonus, a subgroup of
symptomatic myoclonus, with an emphasis on the clin-
ical and pathophysiological heterogeneity of this phe-
nomenon, which could mislead clinicians and result in
insufficient consideration of drugs as the cause of
myoclonus.
We first describe two personally observed cases of
drug-induced myoclonus. Next, we present the results of
our literature search on those drugs reported to cause
myoclonus, including details of the corresponding clin-
ical phenotype and, whenever available, data on the
neuro-anatomical origins and pathophysiological
processes.
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Case description
Case A
Patient A was a 79-year-old woman who developed her
first ever epileptic seizure 2 days after the start of intra-
venous penicillin and ciprofloxacin prescribed for pneu-
monia. On neurological examination after the seizure she
was alert but showed jerky movements of trunk, abdomen,
and arms (particularly the right shoulder) more than of her
legs that she could not suppress (video 1). The spread and
temporal gradient of these jerks were particularly indica-
tive of propriospinal myoclonus. EEG showed no epileptic
phenomena, not even at the time when the movements
occurred during recording. Antibiotic therapy was switched
to claritromycin and ceftazidim, after which the myoclonus
disappeared. The final diagnosis was that of ciprofloxacin
and/or penicillin-induced propriospinal myoclonus.
Case B
Patient B was a 66-year-old man who had been diagnosed
12 years previously with Parkinson’s disease for which he
took levodopa/benserazide 125 mg t.i.d. plus 125 mg b.i.d.
as dispersible tablets, and ropinirole 6 mg b.i.d. His med-
ical history reported a left-sided stereotactic thalamotomy
because of a troublesome tremor of his right hand and a
cervical disc herniation. Because of peak-dose dyskinesias
and marked off periods during the night, amantadine was
started and augmented to 100 mg t.i.d. Slow-release levo-
dopa/benserazide ante noctum was added to the treatment
regimen. One month after these treatment adjustments, the
patient developed involuntary jerks through his whole body
but predominantly in his face and neck, also severely
affecting his speech. These jerks were not sensitive to
stimuli and occurred mainly during action (both positive
and negative) but were also present at rest. During walking,
axial action myoclonus was apparent (video 2). The
remaining examination showed an asymmetric hypoki-
netic-rigid syndrome, the severity of which was similar to
prior examination. Suspecting drug-induced generalized
myoclonus, amantadine was tapered off, and the myoclo-
nus disappeared within 2 weeks.
Methods
Search strategy
We searched PubMed using the MeSH terms ‘‘My-
oclonus/chemically induced’’, ‘‘Myoclonus/etiology’’,
‘‘Myoclonus/pharmacology’’, ‘‘Myoclonus/physiology’’,
‘‘Myoclonus/physiopathology’’, ‘‘Drug-Related Side
Effects and Adverse Reactions’’, and ‘‘Dyskinesia, Drug-
Induced’’. Only articles in English, published before
September 2016, were reviewed for relevance.
Results
Our literature search on drug-induced myoclonus mainly
identified case reports and (mostly small) case series (the
largest involving 32 patients). Table 1 summarizes the
number of cases reported per subclass of drugs associated
with myoclonus, the distribution of myoclonus, and one or
two relevant references per category. The full table with all
references considered (Table 2) is available as supple-
mentary material. Almost all classes of drugs have been
linked to myoclonus. The clinical phenotype covered the
whole spectrum, from a focal to a generalized distribution.
The presumed anatomic structures and neurotransmitters
involved are suggested to differ per causative agent. Drug-
induced myoclonus was usually reversible following
withdrawal of the offending drug [10, 44], and only a
single case of persistent myoclonus has been reported [75].
We here describe the characteristics of myoclonus caused
by the four classes of drugs most often reported in relation
to myoclonus (opiates, antidepressants, antipsychotics, and
antibiotics) and by the group of drugs involved in our case
B (NMDA antagonists).
Opiates
Myoclonus may occur as a result of initial administration,
change, or withdrawal of opiates [19, 32, 47]. Mainly
generalized, but also multifocal and a single case of focal
myoclonus have been described (Table 1, and supple-
mentary Table 2). Opiate-related myoclonus occurs more
frequently in patients concurrently treated with antide-
pressant, antipsychotic, antiemetic, or nonsteroidal anti-
inflammatory drugs [47]. The precise pathophysiology
remains poorly understood. A neuro-excitatory effect of
opioid compounds and metabolites has been attributed to
glutamate activation of N-methyl-D-aspartate (NMDA)
receptors, glycine-mediated disinhibition of neural path-
ways at the cortical or spinal level, antagonism of gamma-
amino-butyric acid (GABA) activity in the spinal cord,
serotonergic and GABAergic pathways in the brainstem,
and dopaminergic pathways in the basal ganglia [32].
Antidepressants
Various classes of antidepressants have been associated
with myoclonus (Table 1, and supplementary Table 2).
Selective serotonin-reuptake inhibitors (SSRIs) can cause
multifocal [30, 67] or generalized myoclonus [48, 64, 86].
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Tricyclic antidepressants (TCAs) can cause either focal
(especially jaw) [26, 54], multifocal [20, 42], and gener-
alized [14, 49, 68, 98] myoclonus. Lithium has been
observed to cause multifocal [11, 20] and generalized [14]
myoclonus. An EEG transient over the contralateral sen-
sorimotor region preceding the myoclonus suggested a
cortical origin of myoclonus in patients treated with a TCA
[20] or lithium [11]. Serotoninergic mechanisms are
probably involved in the generation of antidepressant-in-
duced myoclonus [30]. While SSRIs increase serotonin
levels in the synaptic cleft, TCAs increase serotonin
activity, and lithium facilitates the presynaptic release of
serotonin [20]. A combination of two serotonergic active
drugs, such as a TCA and lithium, appears more likely to
cause myoclonus than a single drug [14, 20].
Antipsychotics
Classic antipsychotics, including haloperidol, have been
reported to cause multifocal myoclonus of both arms,
sensitive to posture [25, 85]; of limbs and of the face [16];
and of the trunk and limbs [93]. Atypical antipsychotics,
including quetiapine and olanzapine, can cause both mul-
tifocal [33, 72] and generalized [29, 73, 92] myoclonus.
The exact pathogenesis of antipsychotic-induced myoclo-
nus has not yet been unraveled, but involvement of sero-
tonergic [16, 72], dopaminergic [93], and GABA-ergic [92]
mechanisms have all been suggested.
Antibiotics
Antibiotic-induced myoclonus mainly occurs in association
with high or toxic doses of antibiotics and/or underlying
renal disease [75]. It is commonly accompanied by other
symptoms, such as altered mental state, seizures (similar to
our case A), aphasia, chorea, and skin rash [75]. Myoclonus
due to b-lactam antibiotics clinically varies from subtle
peri-ocular twitching to generalized myoclonus [75].
Myoclonus due to quinolones can be generalized [21, 38]
or multifocal [81]. It is hypothesized that b-lactam antibi-
otics selectively antagonize [75] and quinolones com-
pletely inhibit [71] gamma aminobutyric acid (GABA)
receptors, decreasing their inhibitory activity at nerve ter-
minals, thus inducing a hyperexcitable neuronal state of the
central nervous system that triggers myoclonus. Sulfon-
amides have been associated with multifocal and general-
ized myoclonus. A causative role of altered dopamine
metabolism due to inhibition of dihydrofolate reductase
[15] as well as increased phenylalanine levels due to the
inhibition of phenylalanine metabolism have been pro-
posed [41]. Multifocal myoclonus that is due to amino-
glycosides has been attributed to NMDA receptor
activation and subsequent excitotoxicity.
NMDA antagonists
Myoclonus due to N-methyl-D-aspartate (NMDA) receptor
antagonists has rarely been reported. Amantadine has been
shown to reduce levodopa-induced dyskinesias [100] but
paradoxically has also been reported to induce jaw myo-
clonus in two patients [31, 70] and generalized myoclonus
in four patients [55, 96]. In addition, memantine gave rise
to myoclonus in patients with dementia [58, 60, 66]. The
mechanism underlying amantadine and memantine induced
myoclonus remains unclear, but might involve altered
levels of dopamine, serotonin, and/or glutamate release
[55, 96].
Conclusion
A French pharmacovigilance database study [7], regis-
tering all compulsorily reported adverse drug reactions
in France, reported an incidence of drug-induced myo-
clonus of 0.2% (423/185.634 reported adverse events
over a 20-year period), which might be an underesti-
mation due to underreporting [7]. Our literature survey is
not suitable to extract epidemiological data, but the large
number of case reports that we identified does suggest
that drug-induced myoclonus is not an uncommon phe-
nomenon in movement disorder consultations. Of course,
we cannot offer certainty about causality for the
observed associations between drugs and myoclonus,
which is inherent to a literature review of case reports
and case series. However, in many cases, myoclonus
appeared shortly after the prescription of a new (and
presumably causally involved) drug, and disappeared
again readily after this same drug was stopped, sug-
gesting a causal relationship.
Our survey—as well as the French pharmacovigilance
database study—found that the most important groups of
drugs with links to myoclonus are: opiates, antidepres-
sants, antipsychotic drugs, and antibiotics. However,
drug-induced myoclonus may also be caused by a wide
variety of other drugs. Drug-induced myoclonus is usu-
ally reversible upon discontinuation of the offending
drug, and this stresses the importance of making the
correct diagnosis of drug-induced myoclonus. Impor-
tantly, the phenomenology of the myoclonus can vary
within a group of drugs and even for one particular drug,
suggesting that the neuro-anatomical generator varies.
From a clinical perspective, this also means that drugs as
a cause cannot be discarded based solely on clinical
myoclonus characteristics. The precise cellular and
neurochemical alterations that make a certain drug cause
myoclonus remain largely unclear and therefore need
further study.
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